No.

Publication Date

Citing Article

1

2022

Angeles C. Tecalco-Cruz, Marina Macías-Silva, Josué Orlando Ramírez-Jarquín, Uri Nimrod Ramírez-Jarquín. Decoding the Therapeutic Implications of the ERα Stability and Subcellular Distribution in Breast Cancer, Frontiers in Endocrinology. 2022; 13: 867448.  https://doi.org/10.3389/fendo.2022.867448

2

2025

Alina Goerg, Gerhard Piendl, Veruschka Albert, Olaf Ortmann, Anja Kathrin Wege, Gero Brockhoff. Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition, BMC Cancer. 2025; 25: 978.  https://doi.org/10.1186/s12885-025-14361-z

3

2025

Taniya Saha, Kiven Erique Lukong. Decoding estrogen receptor and GPER biology: structural insights and therapeutic advances in ERα−positive breast cancer, Frontiers in Oncology. 2025; 15: 1513225.  https://doi.org/10.3389/fonc.2025.1513225

4

2024

Zhenjie Wang, Siyao Che, Zhiqiang Yu. PROTAC: Novel degradable approach for different targets to treat breast cancer, European Journal of Pharmaceutical Sciences. 2024; 198: 106793106793.  https://doi.org/10.1016/j.ejps.2024.106793

5

2022

Zi Liu, Mingxing Hu, Yu Yang, Chenghao Du, Haoxuan Zhou, Chengyali Liu, Yuanwei Chen, Lei Fan, Hongqun Ma, Youling Gong, Yongmei Xie. An overview of PROTACs: a promising drug discovery paradigm, Molecular Biomedicine. 2022; 3: 46.  https://doi.org/10.1186/s43556-022-00112-0

6

2023

Hannah L. Chang, Blake Schwettmann, Heather L. McArthur, Isaac S. Chan. Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response, Journal of Clinical Investigation. 2023; 133: e172156.  https://doi.org/10.1172/JCI172156